A marginal MR threshold (p < 0.05) was used as evidence of a potential pleitropy effect of the genetic instruments for SGLT2 inhibition on prostate cancer via a prostate cancer risk factor. The gene discussed is SLC5A2; the disease is prostate carcinoma.